Salute e Benessere

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option…

Press ReleaseNicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement Option entitles Glaukos to exclusive global license agreements on pre-agreed terms including upfront and milestone payments plus royaltiesGlaukos to fund and conduct NCX 1728 preclinical research activities evaluating it in glaucoma (including neuroprotection) and in other retinal diseasesNicox focused on continued Phase 3 development of lead drug-candidate, NCX 470...
Nasdaq GlobeNewswire
23/09/2024

WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer…

Roche's CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results Dual-stain biomarkers aid in detection of cervical precancer and may reduce the number of women who undergo unnecessary colposcopy procedures while allowing earlier intervention for those who are at higher risk of developing cervical cancer.This recognition follows the American Society for Colposcopy and Cervical...
Nasdaq GlobeNewswire
23/09/2024

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European…

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients 1TD is an involuntary movement disorder that develops in around 15%-25% of patients taking antipsychotic medications for conditions such as schizophrenia, bipolar disorder, and major depressive disorder 2,3 Data presented at the European College of Neuropsychopharmacology Congress (ECNP) in Milan...
Nasdaq GlobeNewswire
23/09/2024

Awareness of life and permanence: RWK & Kuhlmann presents its first collection…

The high-quality workmanship of the kitchen furniture manufactured in Löhne is in accordance with the design standard, whereby RWK & Kuhlmann can refer to its many years of experience. The manufacturer has stood for diligence, longevity and intelligent functionality for generations with its own Kuhlmann brand and also in commissioned production for European furniture stores. The high-quality workmanship of the kitchen furniture manufactured in Löhne is in accordance with the design…
PR Newswire
23/09/2024

Telix to Acquire RLS to Expand North American Manufacturing and Distribution…

The acquisition of RLS is aligned to Telix's investment strategy around vertically integrated supply chain, manufacturing, and distribution, further enabling the delivery of future clinical and commercial radiopharmaceutical products. The Company views this as a necessary measure to ensure product integrity and delivery, and to strengthen and complement existing commercial partnerships. The acquisition of RLS is aligned to Telix's investment strategy around vertically integrated supply chain,...
PR Newswire
23/09/2024

European Wellness and Jilin Hanxing Group Forge Strategic Partnership to Advance…

The agreement outlines plans for a joint venture project to establish a state-of-the-art Regenerative Medicine and Health Complex in Sanya, Hainan, China. This ambitious project is envisioned as a trinity of "medicine, beauty, and health therapy," positioning itself at the forefront of the global wellness industry. The agreement outlines plans for a joint venture project to establish a state-of-the-art Regenerative Medicine and Health Complex in Sanya,Hainan, China. This ambitious…
PR Newswire
21/09/2024

Summit of Whose Future? Girls Have the Answers: Leaders Must Listen

At a demonstration near the UN, alongside life-size cutouts of world leaders dressed ironically as "girl experts", the activists delivered a strong message: world leaders aren't the experts on what girls want for their futures – girls are. At a demonstration near the UN, alongside life-size cutouts of world leaders dressed ironically as "girl experts", the activists delivered a strong message: world leaders aren't the experts on what girls want for their futures – girls are…
PR Newswire
21/09/2024

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS…

As a leader in neuroscience,Teva is committed to researching new treatment innovations that mayhelp address unmet needs in treating schizophrenia , including TEV-'749Currently, there is no long-acting olanzapine treatment option available for the treatment of schizophrenia that does not contain a boxed warning forPost-Injection Delirium/Sedation Syndrome (PDSS)New Phase 3 SOLARIS and Phase 1 safety data show no incidence of PDSS in study...
Nasdaq GlobeNewswire
21/09/2024

New Data Provide Treatment Insights into Options for Switching Adult Patients…

As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and decisions for patients and HCPsNew data demonstrate switching to UZEDY at four weeks after the last dose of once-monthly RBP-7000 provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identifiedN...
Nasdaq GlobeNewswire
21/09/2024

Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as…

AHMEDABAD, India, Sept. 21, 2024 /PRNewswire/ -- Intas Pharmaceuticals Limited ("Intas") has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of HETRONIFLY® (serplulimab, approved as Hansizhuang in China), in European markets. AHMEDABAD,India , Sept. 21, 2024 /PRNewswire/ -- Intas Pharmaceuticals Limited ("Intas") has announced that the Committee for Medicinal…
PR Newswire
21/09/2024

Translumina Therapeutics, India's largest domestic player in the coronary stents…

Echoing this sentiment, Punita Sharma Arora, Co-Founder & Vice-Chairman of Translumina, added, "We've been present in international markets for more than five years now and have built up a strong direct presence in Europe & South Asia. In just the last one year, we have invested in a direct presence LATAM & SEA, and now with the addition of the MENA region, we have full conviction that our comprehensive product portfolio will be able to reach every corner of the world."…
PR Newswire
21/09/2024

European Wellness Unveils Premier Medical Wellness Center in Kota Kinabalu…

Chief Minister Hajiji praised the vision and commitment of the founders, emphasizing how the center will enhance Sabah's healthcare capabilities and position the region as a prominent destination for medical wellness tourism. "This facility is a game-changer for Sabah, combining state-of-the-art medical science with our unique natural environment," said Hajiji. "It not only strengthens our local healthcare sector but also boosts Sabah's standing on the global medical tourism…
PR Newswire
21/09/2024

BIOVAXYS ANNOUNCES UPSIZING OF PRIVATE PLACEMENT

To date, the Company has issued an aggregate of 17,312,340 Units in connection with the Private Placement. Closing of the Private Placement is subject to receipt of all necessary regulatory and other approvals. All securities to be issued pursuant to the Private Placement will be subject to a statutory hold period of four months from the date of issuance in accordance with applicable securities legislation. The Company intends to use the net proceeds of the Private Placement...
PR Newswire
21/09/2024

Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in…

Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free survival (PFS), compared to standard-of-care in newly diagnosed adult patients not eligible for...
Nasdaq GlobeNewswire
21/09/2024

ChemoMetec makes offer to buy Ovizio Imaging Systems SA

ANNOUNCEMENT NO. 276 20 September 2024 ChemoMetec makes offer to buy Ovizio Imaging Systems SAChemoMetec has submitted an indicative offer to buy Belgian company Ovizio Imaging Systems ('Ovizio'), which has been accepted by the company's group of owners. ChemoMetec now has three weeks to carry out a due diligence, and if the outcome of this is positive, ChemoMetec will most likely proceed with the acquisition.Ovizio has developed a cell counter based on holographic microscopy...
Nasdaq GlobeNewswire
20/09/2024

Coloplast A/S - Trading in Coloplast shares by board members, executives or…

Please see enclosed pdf. Attachment 20092024_trading_in_shares_LRA
Nasdaq GlobeNewswire
20/09/2024

Global Medical Radiation Detection Market Set to Grow from $1.26B in 2024 to…

Browse in-depth TOC on "Medical Radiation Detection Market" Browse in-depth TOC on "Medical Radiation Detection Market" 588 - Tables 48 - Figures 424 - Pages The medical radiation detection, monitoring & safety market has been segmented into Personal dosimeters, Area Process Monitors, Environment Radiation Monitors, Surface Contamination Monitors, Radioactive Material Monitors, and Other Radiation Detection and Monitoring Products categories on the basis of product...
PR Newswire
20/09/2024

Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new…

European Commission grants conditional marketing authorization for Iqirvo ®(elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows positive CHMP opinion based on ELATIVE phase III trial data, which demonstrated significant efficacy over placebo and was well-tolerated with an acceptable safety profile This new European approval reinforces Ipsen's commitment to advancing medical innovations to treat people...
Nasdaq GlobeNewswire
20/09/2024

Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed

Bagsværd, Denmark, 20 September 2024– Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [ Link ].The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose of monlunabant compared to placebo on body weight after 16 weeks in 243...
Nasdaq GlobeNewswire
20/09/2024

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted…

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted COVID-19 vaccine generates a substantially improved response against multiple circulating Omicron JN.1 sublineages as did the Omicron JN.1-adapted COVID-19 vaccine authorized by the European Commission in July 2024Doses will be ready to ship to applicable European Union member states as...
Nasdaq GlobeNewswire
20/09/2024

Press Release: Dupixent recommended for EU approval by the CHMP to treat…

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion of children on Dupixent achieved histological remission, compared to placebo, consistent with improvements seen in adults and adolescentsIf approved, Dupixent would be the first and only medicine in the EU indicated for EoE in this age groupParis and Tarrytown, NY, September 20, 2024...
Nasdaq GlobeNewswire
20/09/2024

Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of…

Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 studyData presented at ECTRIMS show that tolebrutinib, a brain-penetrant BTK inhibitor, addresses disability accumulation that occurs independently from relapse activityGlobal regulatory submissions will begin in H2 2024Paris, September 20, 2024.Positive results from the HERCULES phase 3 study in people with non-relapsing...
Nasdaq GlobeNewswire
20/09/2024

UNION therapeutics to present orismilast Phase 2b results in atopic dermatitis…

"Despite the current developments of new treatments in AD, there is a clear need for safe and efficacious oral treatments. Impact on patients' experience of itch and pain along with lesional improvements are key to determine the relevance of a treatment", says Prof. Dr. Eric Simpson. "I am excited to present the results from the Phase 2b ADESOS study at the EADV Congress 2024, showing that orismilast offers the promise as a novel treatment option in AD with early impact on…
PR Newswire
20/09/2024

Funeral Services Market to Reach $88.6 Billion, Globally, by 2033 at 3.8% CAGR…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A06825 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A06825 Prime determinants of growth Rise in geriatric population, which is prone to critical illnesses, is a major factor that boosts the growth of the market. Cultural shifts toward personalized and meaningful ceremonies drive demand for customized funeral services, catering to...
PR Newswire
20/09/2024
Altri  Comunicati